LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 23, Issue 17, Pages 9958
Publisher
MDPI AG
Online
2022-09-02
DOI
10.3390/ijms23179958
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer
- (2022) An-Ping Shi et al. Frontiers in Immunology
- Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome
- (2022) Elisa Ciraolo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma
- (2022) Yi Luo et al. Frontiers in Endocrinology
- Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
- (2022) Patrick Schöffski et al. Journal for ImmunoTherapy of Cancer
- A new risk factor indicator for papillary thyroid cancer based on immune infiltration
- (2021) Zhou Yang et al. Cell Death & Disease
- LAG3’s Enigmatic Mechanism of Action
- (2021) Colin G. Graydon et al. Frontiers in Immunology
- LAG-3 expression in the inflammatory microenvironment of glioma
- (2021) Maximilian J. Mair et al. JOURNAL OF NEURO-ONCOLOGY
- Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3
- (2021) Shafei Wu et al. Frontiers in Immunology
- The Immune Checkpoint Inhibitor LAG-3 and Its Ligand GAL-3 in Vulvar Squamous Neoplasia
- (2021) Margaret M. Cocks et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- Improving Breast Cancer Responses to Immunotherapy—a Search for the Achilles Heel of the Tumor Microenvironment
- (2021) Sarah Jenkins et al. Current Oncology Reports
- Bispecific Antibodies: From Research to Clinical Application
- (2021) Jiabing Ma et al. Frontiers in Immunology
- LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer
- (2021) Lena Seifert et al. Cancers
- LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
- (2021) Christian Sordo-Bahamonde et al. Cancers
- LAG3 and its emerging role in cancer immunotherapy
- (2021) Miao Wang et al. Clinical and Translational Medicine
- A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes
- (2021) Carla Calagua et al. CLINICAL CANCER RESEARCH
- A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.
- (2021) Elena Garralda et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.
- (2021) Omid Hamid et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).
- (2021) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade
- (2021) Ronglai Shen et al. Science Translational Medicine
- Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer
- (2021) Elisabeth S. Stovgaard et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples
- (2021) Qiang Liu et al. Frontiers in Immunology
- LAG3 and Its Ligands Show Increased Expression in High-Risk Uveal Melanoma
- (2021) Zahra Souri et al. Cancers
- LAG-3 Expression Predicts Outcome in Stage II Colon Cancer
- (2021) Gaëlle Rhyner Agocs et al. Journal of Personalized Medicine
- The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
- (2021) Andrea Botticelli et al. Journal of Personalized Medicine
- 53P Expression of sodium-dependent phosphate transporter NaPi2b is downregulated in malignant ovarian tumors after neoadjuvant chemotherapy
- (2021) A.K. Nurgalieva et al. ANNALS OF ONCOLOGY
- Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance
- (2021) Daniel J. Shepherd et al. MODERN PATHOLOGY
- Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment
- (2021) Liyuan Song et al. BMC Pulmonary Medicine
- 89 The immune marker LAG-3 increases the predictive value of CD38+ immune cells for survival outcome in immunotherapy-treated hepatocellular carcinoma
- (2021) Chun Chau Lawrence Cheung et al. Journal for ImmunoTherapy of Cancer
- Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer
- (2020) Sevda Jafari et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Ectopic expression of LAG‐3 in non–small‐cell lung cancer cells and its clinical significance
- (2020) Chenglong Ma et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- Light-induced radiosynthesis of 89ZrDFO-azepin-onartuzumab for imaging the hepatocyte growth factor receptor
- (2020) Simon Klingler et al. JOURNAL OF NUCLEAR MEDICINE
- OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody
- (2020) Hirofumi Ohmura et al. BRITISH JOURNAL OF CANCER
- FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity
- (2020) Matthew Kraman et al. CLINICAL CANCER RESEARCH
- Differential immune pathways in classic and mixed variants of anaplastic thyroid cancer.
- (2020) Hannah J Young et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunohistochemistry analyses of LAG-3 expression across different tumor types and co-expression with PD-1.
- (2020) Francine Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis
- (2020) Stephanie M Slevin et al. Journal of Crohns & Colitis
- LAG3(LAG-3,CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
- (2020) Niklas Klümper et al. Journal for ImmunoTherapy of Cancer
- Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis
- (2020) Mengzhou Guo et al. Journal of Translational Medicine
- Glioma patient profiling reveals the dominant immune suppressive adenosine axis is refractory to immune function restoration
- (2020) Martina Ott et al. JCI Insight
- LAG-3: from molecular functions to clinical applications
- (2020) Takumi Maruhashi et al. Journal for ImmunoTherapy of Cancer
- The critical role of CD4+ T cells in PD-1 blockade against MHC-II–expressing tumors such as classic Hodgkin lymphoma
- (2020) Joji Nagasaki et al. Blood Advances
- Depletion of LAG‐3 + T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781
- (2020) Joanne Ellis et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time’s a Charm
- (2020) Quentin Lecocq et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Antibody and antibody fragments for cancer immunotherapy
- (2020) Weizhi Chen et al. JOURNAL OF CONTROLLED RELEASE
- Counteracting CAR T cell dysfunction
- (2020) Mansour Poorebrahim et al. ONCOGENE
- Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer
- (2020) Marie Christine Wulff Westergaard et al. Cancers
- Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma
- (2020) Layal El Halabi et al. Clinical Lymphoma Myeloma & Leukemia
- An immunogenic NSCLC microenvironment is associated with favorable survival in lung adenocarcinoma
- (2019) Kevin B. Givechian et al. Oncotarget
- Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: an ATC-like and a PDTC-like
- (2019) Riccardo Giannini et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Immune Infiltration in Renal Cell Carcinoma
- (2019) Shichao Zhang et al. CANCER SCIENCE
- TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer
- (2019) Jitka Fucikova et al. CLINICAL CANCER RESEARCH
- Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.
- (2019) Ila J Datar et al. CLINICAL CANCER RESEARCH
- AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer
- (2019) Luc Dirix et al. Future Oncology
- Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
- (2019) Nataliya Volodymyrivna Uboha et al. JOURNAL OF CLINICAL ONCOLOGY
- First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.
- (2019) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- LAG-3 and GAL-3 in Endometrial Carcinoma
- (2019) Lisa A. Friedman et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target
- (2019) Su Jin Lee et al. JOURNAL OF IMMUNOTHERAPY
- Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3 Knock-In Mice
- (2019) Elena Burova et al. MOLECULAR CANCER THERAPEUTICS
- PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma
- (2019) Henning Zelba et al. Cancer Immunology Research
- 1197PA phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
- (2019) A Spreafico et al. ANNALS OF ONCOLOGY
- Data Mining of Prognostic Microenvironment-Related Genes in Clear Cell Renal Cell Carcinoma: A Study with TCGA Database
- (2019) Bin Chen et al. DISEASE MARKERS
- Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
- (2019) Katsiaryna Marhelava et al. Cancers
- The co-expression characteristics of LAG3 and PD-1 on the T cells of patients with breast cancer reveal a new therapeutic strategy
- (2019) Huimin Du et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival
- (2019) Lei Tu et al. INTERNATIONAL JOURNAL OF CANCER
- Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients
- (2018) Qiang Ma et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells
- (2018) Andreia C. Lino et al. IMMUNITY
- Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction
- (2018) Bhagyashree Bhagwat et al. JOURNAL OF IMMUNOLOGICAL METHODS
- The “less-is-more” in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
- (2018) Natasha A. Pereira et al. mAbs
- Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer
- (2018) Guoying Zhou et al. OncoImmunology
- Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood
- (2018) Na Li et al. Cancer Biomarkers
- Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies
- (2018) David Savitsky et al. CANCER RESEARCH
- Abstract 5626: Preclinical characterization of Sym022, a novel anti-LAG3 antibody
- (2018) Michael M. Grandal et al. CANCER RESEARCH
- Genomic characterization of six virus-associated cancers identifies changes in the tumor immune microenvironment and altered genetic programs
- (2018) Frederick S. Varn et al. CANCER RESEARCH
- Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma
- (2018) Sarah Harris-Bookman et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
- (2018) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- TSR-033, a novel therapeutic antibody targeting LAG-3 enhances T cell function and the activity of PD-1 blockade in vitro and in vivo
- (2018) Srimoyee Ghosh et al. MOLECULAR CANCER THERAPEUTICS
- LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
- (2018) Takumi Maruhashi et al. NATURE IMMUNOLOGY
- Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer
- (2018) Emelie Rådestad et al. OncoImmunology
- Function and regulation of LAG3 on CD4 + CD25 - T cells in non-small cell lung cancer
- (2017) Qin-Yun Ma et al. EXPERIMENTAL CELL RESEARCH
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
- (2017) Yayi He et al. Journal of Thoracic Oncology
- Transcriptomic analysis of purified human cortical microglia reveals age-associated changes
- (2017) Thais F Galatro et al. NATURE NEUROSCIENCE
- Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses
- (2017) Valerie Chew et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Novel mutational landscapes and expression signatures of lung squamous cell carcinoma
- (2017) Donghai Xiong et al. Oncotarget
- Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma
- (2017) Zhi-Zhang Yang et al. Oncotarget
- CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells
- (2017) Yongping Zhang et al. Frontiers of Medicine
- Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling
- (2017) Peter J. Siska et al. OncoImmunology
- Galectin 3 as a guardian of the tumor microenvironment
- (2016) Peter P. Ruvolo BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer
- (2016) Qingda Meng et al. JOURNAL OF IMMUNOTHERAPY
- Adult mouse cortical cell taxonomy revealed by single cell transcriptomics
- (2016) Bosiljka Tasic et al. NATURE NEUROSCIENCE
- Pathological -synuclein transmission initiated by binding lymphocyte-activation gene 3
- (2016) X. Mao et al. SCIENCE
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
- (2016) Wei-Wei Deng et al. OncoImmunology
- Abstract 2502: Immunization with minicircle and mini-intronic DNA vectors induce LAG-3 expressing CD8+ T cells and inferior anti-tumor responses
- (2015) Viswa Teja Colluru et al. CANCER RESEARCH
- Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4 + T- Cells, Which Dampen CD8 + T-cell Antitumor Reactivity
- (2015) Marco Donia et al. CANCER RESEARCH
- POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
- (2015) I. C. van Gool et al. CLINICAL CANCER RESEARCH
- Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
- (2015) N. A. Giraldo et al. CLINICAL CANCER RESEARCH
- Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
- (2015) J. M. Taube et al. CLINICAL CANCER RESEARCH
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
- (2015) Ruea-Yea Huang et al. Oncotarget
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- Trafficking of LAG-3 to the Surface on Activated T Cells via Its Cytoplasmic Domain and Protein Kinase C Signaling
- (2014) Joonbeom Bae et al. JOURNAL OF IMMUNOLOGY
- Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3
- (2014) Chiara Camisaschi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex
- (2014) Y. Zhang et al. JOURNAL OF NEUROSCIENCE
- The effect of immune microenvironment on the progression and prognosis of colorectal cancer
- (2014) Jinxiang Chen et al. MEDICAL ONCOLOGY
- The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells
- (2014) Antoine Marçais et al. NATURE IMMUNOLOGY
- Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
- (2013) H-B Jie et al. BRITISH JOURNAL OF CANCER
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
- (2011) Lukas Baitsch et al. JOURNAL OF CLINICAL INVESTIGATION
- MHC Class II Engagement by Its Ligand LAG-3 (CD223) Contributes to Melanoma Resistance to Apoptosis
- (2011) P. Hemon et al. JOURNAL OF IMMUNOLOGY
- Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4
- (2010) Seng-Ryong Woo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
- (2010) C. Camisaschi et al. JOURNAL OF IMMUNOLOGY
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis
- (2009) C. J. Workman et al. JOURNAL OF IMMUNOLOGY
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
- Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
- (2008) Shawn D Blackburn et al. NATURE IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started